Muscle protein synthesis (MPS) is the anabolic metabolic process in which amino acids are assembled into muscle proteins—primarily myofibrillar proteins (actin, myosin) that form the contractile apparatus, but also sarcoplasmic and mitochondrial proteins. MPS is regulated by nutrient sensing (especially leucine concentration), mechanical loading (resistance exercise activates mechanoreceptors), and endocrine signals (insulin, IGF-1, testosterone). The balance between MPS and muscle protein breakdown (MPB) determines net muscle protein balance and thus muscle mass over time.
Imagine a construction site where new buildings are going up. MPS is the construction crew actively laying bricks (amino acids) to build new structures (muscle proteins). The foreman (mTOR) stands at the gate checking two things: first, that enough bricks have been delivered (leucine threshold reached), and second, that the architect has approved expansion (mechanical loading signal from exercise). When both conditions are met, the foreman blows the whistle and the crew swings into action—cranes (ribosomes) lift materials into place, and the building grows taller and stronger. Insulin acts like a delivery truck bringing even more bricks to the site and opening the gates wider. But if energy runs low (AMPK activation), the city inspector shuts down construction to conserve resources. Aging is like the foreman getting hard of hearing—you need louder signals (more leucine, more loading) to get the same construction response. The building crew works in shifts: they're most active for 24-48 hours after the architect's approval (post-exercise), then gradually slow down until the next signal arrives.
MPS is orchestrated primarily through the mTORC1 (mechanistic Target of Rapamycin Complex 1) pathway, with mechanical and nutritional inputs converging on this master regulator:
Leucine Sensing Pathway:
- Leucine binds to cytosolic sensor Sestrin2, causing conformational change
- Sestrin2 releases GATOR2 (GAP Activity Towards Rags 2)
- GATOR2 inhibits GATOR1, which normally suppresses mTORC1
- Result: mTORC1 activation when leucine ≥2-3g per meal
Insulin/IGF-1 Pathway:
- Insulin or IGF-1 binds receptor tyrosine kinases
- Activates PI3K (phosphoinositide 3-kinase) → PIP3 formation
- PIP3 recruits PDK1 and Akt to membrane
- Akt phosphorylates TSC2 (tuberous sclerosis complex 2), inhibiting it
- TSC1/TSC2 normally suppresses Rheb (Ras homolog enriched in brain)
- Rheb-GTP directly activates mTORC1
Mechanical Loading Pathway:
- Resistance exercise creates mechanical tension sensed by focal adhesion kinase (FAK)
- Phosphatidic acid (PA) produced from phospholipase D activation
- PA directly binds and activates mTORC1
- Satellite cell activation provides additional myonuclei for sustained hypertrophy
mTORC1 Downstream Effectors:
- mTORC1 phosphorylates S6K1 (ribosomal protein S6 kinase) → ribosomal biogenesis
- mTORC1 phosphorylates 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1)
- Phosphorylated 4E-BP1 releases eIF4E → translation initiation complex formation
- Result: increased ribosomal protein synthesis rate (fractional synthetic rate, FSR)
Inhibitory Regulation:
- AMPK (activated when ATP:AMP ratio low) phosphorylates TSC2, activating it → mTORC1 inhibition
- Cortisol increases REDD1 expression → TSC1/TSC2 activation → mTORC1 suppression
- Myostatin binds ActRIIB receptor → Smad2/3 → inhibits Akt → reduces mTORC1 activity
graph TD
A[Leucine ≥2-3g] -->|binds| B[Sestrin2]
B -->|releases| C[GATOR2]
C -->|inhibits| D[GATOR1]
D -.suppresses.-> E[mTORC1]
F[Insulin/IGF-1] -->|receptor| G[PI3K]
G --> H[Akt]
H -->|inhibits| I[TSC1/TSC2]
I -.suppresses.-> J[Rheb-GTP]
J -->|activates| E
K[Mechanical Load] --> L["FAK + PA"]
L -->|direct activation| E
E -->|phosphorylates| M[S6K1]
E -->|phosphorylates| N[4E-BP1]
M --> O[Ribosomal Biogenesis]
N --> P[Translation Initiation]
O --> Q["↑ Muscle Protein Synthesis"]
P --> Q
R[AMPK] -.inhibits.-> E
S[Cortisol] -->|via REDD1| I
T[Myostatin] -.inhibits.-> H
Temporal Dynamics:
- MPS peaks 1-2 hours post-protein ingestion
- Exercise-induced MPS elevation lasts 24-48 hours (untrained) or up to 72 hours (trained with eccentric damage)
- Baseline FSR in sedentary adults: ~0.04-0.05%/hour
- Post-feeding FSR: ~0.10-0.15%/hour
- Post-exercise + feeding FSR: ~0.15-0.20%/hour
MPS is the anabolic counterpart in the muscle protein balance equation (MPS - MPB = net balance). Understanding MPS regulation is critical for:
Post-Injury Recovery:
After muscle injury, MPB initially dominates (days 0-3) as damaged proteins are cleared. Starting leucine supplementation "after 3 days" (as per Module 5 protocol) strategically times mTOR activation to the repair phase when fibroblasts and satellite cells are active, maximizing regenerative MPS without interfering with necessary inflammatory breakdown. Dosing: 2-3g leucine per meal, ideally 3-4 times daily.
Sarcopenia and Aging:
Anabolic resistance develops with age—older adults require ~40g protein per meal (vs. 20g in young adults) to achieve equivalent MPS response. This reflects reduced leucine sensing sensitivity, decreased ribosomal capacity, and chronic low-grade inflammation dampening mTOR signaling. Clinical threshold: if patient >60 years shows declining muscle mass despite adequate protein intake, suspect anabolic resistance requiring higher leucine doses (4-5g) or metabolic stress reduction (address inflammation, insulin resistance).
Performance Nutrition:
Athletes require sustained positive protein balance. The "muscle full" effect occurs ~3-4 hours post-feeding when MPS returns to baseline despite elevated amino acids—this supports protein distribution across 4-5 meals rather than 2-3 large boluses. Total daily protein for hypertrophy: 1.6-2.2g/kg bodyweight, with 0.4-0.55g/kg per meal optimizing each MPS pulse.
Sleep Deprivation:
Even one night of partial sleep deprivation reduces MPS by ~18% and increases MPB, shifting net balance negative. Chronic sleep restriction is a hidden driver of treatment-resistant sarcopenia or impaired recovery. Clinical pearl: if progress stalls despite adequate protein/training, investigate sleep quality and duration.
mTOR Inhibition Trade-off:
While mTOR activation drives MPS and hypertrophy, it simultaneously inhibits autophagy. The evolutionary mismatch: constant high-protein feeding and anabolic signaling may support muscle mass but reduce cellular quality control. This connects to the 5+2 metamodel—intermittent fasting or protein cycling allows periodic mTOR suppression and autophagy activation, balancing anabolism with cellular housekeeping.
Practical Intervention Thresholds:
- Leucine dose: 2-3g per meal (≥40mg/kg bodyweight)
- Protein timing: within 2 hours post-exercise for maximal synergy
- Resistance training: 60-85% 1RM, 3-4 sets to near-failure stimulates 48h MPS elevation
- Post-injury nutrition: delay leucine until day 3-4 post-trauma to avoid premature anabolic signaling during inflammatory clearance phase
- 2-3g leucine per meal represents the threshold dose to saturate Sestrin2 binding and maximize mTORC1 activation
- MPS elevation persists 24-48 hours post-resistance exercise in trained individuals, up to 72 hours with novel eccentric loading
- Fractional synthetic rate (FSR) measures muscle protein pool replacement: baseline ~0.04%/hour, post-feeding peak ~0.15%/hour
- 20g high-quality protein maximally stimulates MPS in young adults; 40g required in older adults (anabolic resistance threshold)
- mTORC1 activation simultaneously inhibits autophagy—creating an anabolic-catabolic seesaw
- Insulin enhances MPS by ~30% when combined with amino acids (synergistic via PI3K-Akt pathway)
- Cortisol >500 nmol/L sustained suppresses MPS via REDD1-mediated mTOR inhibition
- Sleep deprivation reduces MPS by 18% and increases MPB by 21% within 24 hours
- Satellite cells must be activated and donate nuclei for fibers to exceed baseline myonuclear domain (~2000 ÎĽmÂł/nucleus)
- Aging reduces ribosomal density and leucine sensitivity—doubling leucine dose can partially rescue anabolic resistance
- mTOR — master regulatory kinase integrating nutrient, energy, and mechanical signals to activate ribosomal protein synthesis
- L-leucine — essential amino acid that binds Sestrin2 to release mTORC1 inhibition; 2-3g threshold dose
- muscle protein breakdown — catabolic counterpart; net muscle balance = MPS - MPB
- fractional synthetic rate — quantitative biomarker measuring percentage of muscle protein pool replaced per unit time
- S6K — ribosomal protein S6 kinase phosphorylated by mTORC1 to drive ribosomal biogenesis
- resistance training — mechanical loading stimulus activating FAK and phosphatidic acid to directly stimulate mTORC1 for 24-48h
- satellite cells — muscle stem cells that donate myonuclei required for fiber hypertrophy beyond baseline nuclear domain capacity
- insulin — anabolic hormone enhancing MPS ~30% via PI3K-Akt-mTORC1 pathway when combined with amino acids
- IGF-1 — insulin-like growth factor activating same PI3K-Akt pathway; mediates exercise-induced anabolic signaling
- testosterone — anabolic steroid hormone increasing protein synthesis via androgen receptor genomic signaling and mTOR sensitization
- autophagy — cellular quality control process inhibited by mTORC1 activation; requires periodic mTOR suppression
- AMPK — energy sensor kinase that phosphorylates TSC2 to suppress mTORC1 when ATP:AMP ratio is low
- cortisol — glucocorticoid hormone that increases REDD1 expression and activates TSC1/TSC2 to inhibit mTORC1 and MPS
- sarcopenia — age-related muscle loss driven by anabolic resistance (reduced MPS responsiveness to leucine and exercise)
- muscle injury — creates biphasic response: MPB dominance days 0-3 for debris clearance, MPS dominance days 3+ for repair
- muscle hypertrophy — net outcome when sustained MPS exceeds MPB over weeks to months; requires progressive mechanical overload
- sleep — critical recovery window when MPS peaks due to growth hormone pulsatility and reduced cortisol; deprivation impairs MPS 18%
- amino acids — building blocks for synthesis and signaling molecules; leucine is uniquely sensed via Sestrin2-GATOR pathway
- BCAAs — branched-chain amino acids (leucine, isoleucine, valine); leucine is primary mTORC1 activator, others provide substrate
- protein intake — must meet threshold of 1.6-2.2g/kg/day for athletes; timing and distribution across meals modulates MPS peaks
- Akt — serine/threonine kinase downstream of insulin/IGF-1 that phosphorylates TSC2 to release mTORC1 from inhibition
- PI3K — phosphoinositide 3-kinase activated by insulin/IGF-1 receptor; generates PIP3 to recruit Akt
- ribosomal biogenesis — S6K1 target process increasing translational capacity; rate-limiting for sustained MPS elevation
- mitochondrial biogenesis — parallel process to myofibrillar MPS; requires PGC-1α activation and balanced anabolic-catabolic cycling
- inflammation — systemic IL-6, TNF-α elevations reduce insulin/IGF-1 signaling efficiency and create anabolic resistance
- anabolic resistance — age- or inflammation-related reduction in MPS response to leucine/exercise; requires higher stimuli to overcome
- intermittent fasting — dietary pattern alternating mTOR activation (feeding) and autophagy (fasting) to balance anabolism and cellular quality control
- Module 5 — Connective tissue injury protocols, post-injury leucine timing strategy
- Module 10 — Movement and nutrition integration, resistance training stimulus for MPS